NASDAQ:KYTX Kyverna Therapeutics Q4 2024 Earnings Report $6.99 -0.08 (-1.13%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$7.06 +0.07 (+1.06%) As of 09/24/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kyverna Therapeutics EPS ResultsActual EPS-$0.88Consensus EPS -$0.87Beat/MissMissed by -$0.01One Year Ago EPSN/AKyverna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKyverna Therapeutics Announcement DetailsQuarterQ4 2024Date3/27/2025TimeBefore Market OpensConference Call DateThursday, March 27, 2025Conference Call Time4:00PM ETUpcoming EarningsKyverna Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesReportAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual report(10-K) Kyverna Therapeutics Earnings HeadlinesKYTX stock reverses gains after one-year cell therapy trial data — but CEO says disease burden justifies a premium priceSeptember 24 at 7:09 PM | msn.comKyverna stock jumps on positive one-year therapy dataSeptember 24 at 2:07 PM | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials TranscriptSeptember 24 at 2:00 PM | seekingalpha.comOne-Year Benefits Sustain Momentum For Kyverna's Autoimmune CAR-T Therapy; Stock UpSeptember 24 at 8:13 AM | rttnews.comKyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized ...September 24 at 8:13 AM | finance.yahoo.comSee More Kyverna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email. Email Address About Kyverna TherapeuticsKyverna Therapeutics (NASDAQ:KYTX) is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases. The company is working to apply chimeric antigen receptor T-cell (CAR T) technology, traditionally used in certain blood cancers, to conditions in which the immune system attacks the body’s own tissues. Kyverna’s lead investigational product, KYV-101, is an autologous, fully human CD19-directed CAR T-cell therapy designed to eliminate B cells that contribute to autoimmune disease. The therapy is being evaluated in clinical studies involving severe autoimmune conditions, including systemic sclerosis, lupus nephritis, myasthenia gravis and multiple sclerosis. Kyverna is also developing additional candidates and capabilities through its cell therapy platform. Founded in 2018, Kyverna Therapeutics is headquartered in Emeryville, California. Its clinical development activities have included sites in the United States and Europe. The company’s leadership has included Peter Maag as chief executive officer, with the organization focused on advancing potentially disease-modifying treatments for patients with serious autoimmune disorders.View Kyverna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
